September 11, 2019
BioTissue Expands National Footprint, Ramps Up Sales Force by More than 25 Percent
Organization Prepares for Submission of Investigational New Drug Applications and Transition into a Biologics Provider
Miami, FL – September 11, 2019 – BioTissue®, Inc., a TissueTech,™ Inc. company, and pioneer and market leader in the development and clinical application of Cryopreserved Amniotic Membrane (CAM) products for ocular surface disease and injury, today announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients.
“A growing body of scientific evidence has cemented CAM as a mainstay treatment for ocular surface diseases”, said Grady Grant III, TissueTech Vice President of Sales. “We are excited to be increasing our sales presence and are well positioned for continued growth. I’m thrilled to welcome our new hires to the organization and am confident this will better position us to continue to grow our user base.”
BioTissue’s Prokera® family of products are the only FDA-cleared amniotic membrane medical devices for the treatment of eye disease and injury. Prokera, along with the company’s surgical products, AmnioGraft® and AmnioGuard®, contain the only cryopreserved amniotic membrane that has been recognized by the FDA for its anti-scarring, anti-inflammation, and anti-angiogenesis properties.
BioTissue is a wholly owned subsidiary of TissueTech, which recently closed on an $82.25 million round of Preferred C equity financing led by EW Healthcare Partners.
“This funding not only helps us support ongoing investments in our commercial activities such as this, but also helps drive the clinical research, manufacturing and product development activities needed to support our transformation to a biologics therapy provider,” said TissueTech co-founder and Chief Executive Officer Amy Tseng. “We’re excited to announce the expansion and to carry the great momentum we are building into an amazing year of growth and development in 2020.”
About BioTissue
BioTissue, Inc., a TissueTech, Inc. company, is the market leader in the clinical application of cryopreserved amniotic membrane-based products for the treatment of diseases and disorders of the ocular surface. Established in 1997, BioTissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals manage ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis, dry eye, pterygium and dry eye.
About TissueTech, Inc.
TissueTech is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care and soft tissue products to support regenerative tissue healing using amniotic membrane and umbilical cord birth tissue donated from healthy, pre-screened mothers after elective cesarean section delivery of a live birth. The organization brings a skilled approach to innovation in evidence-based medicine with more than 20 years of clinical experience and more than 30 years of scientific research funded by the National Institutes of Health. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at www.biotissue.com.
